Why is dexamethasone (Decadron) given as an overnight low‑dose suppression test to rule out Cushing syndrome, and how should the morning cortisol result be interpreted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Why Dexamethasone is Given and How to Interpret Morning Cortisol

Dexamethasone is given as an overnight suppression test because it exploits a fundamental pathophysiologic defect in Cushing syndrome: the failure to suppress cortisol production despite supraphysiologic glucocorticoid administration, which normally inhibits ACTH and cortisol secretion in healthy individuals. 1, 2

The Physiologic Principle

In normal physiology, administering a supraphysiologic dose of the synthetic glucocorticoid dexamethasone suppresses the hypothalamic-pituitary-adrenal axis. This leads to decreased ACTH secretion from the pituitary, which in turn causes the adrenal glands to stop producing cortisol. In Cushing syndrome of any etiology (pituitary, adrenal, or ectopic ACTH), this normal negative feedback mechanism is disrupted, and cortisol production continues despite dexamethasone administration. 2

The test specifically targets one of three key pathophysiologic derangements in Cushing syndrome: (1) loss of normal diurnal cortisol rhythm, (2) failure to discontinue cortisol production despite absence of ACTH stimulation, and (3) excess cortisol production. 1

How to Perform the Test

The overnight 1-mg dexamethasone suppression test (DST) is performed by:

  • Administering 1 mg of dexamethasone orally between 11 PM and midnight 1, 3
  • Measuring fasting plasma cortisol between 8 AM and 9 AM the following morning 1, 4

Interpreting the Morning Cortisol Result

Normal Response (Rules OUT Cushing Syndrome)

A morning cortisol <1.8 μg/dL (50 nmol/L) has the best negative predictive value for Cushing syndrome and effectively excludes the diagnosis. 1, 4

This cutoff provides:

  • Sensitivity approaching 95-100% when used in appropriate populations 1, 4
  • High specificity of approximately 87-94% 1, 4

Abnormal Response (Suggests Cushing Syndrome)

A morning cortisol ≥1.8 μg/dL indicates failure of suppression and warrants further evaluation. 1

However, interpretation requires nuance:

  • Cortisol >5 μg/dL (138 nmol/L): Strongly suggests Cushing syndrome, though this higher cutoff reduces sensitivity 4
  • Cortisol 1.8-5 μg/dL: Gray zone requiring additional testing 1
  • For adrenal incidentalomas specifically: Cortisol <1.8 μg/dL excludes autonomous cortisol secretion; >5 μg/dL generally identifies overt Cushing syndrome 4

The Two-Test Rule

The Endocrine Society strongly recommends that any abnormal result be followed by a second confirmatory test before proceeding to determine the etiology of Cushing syndrome. 2 Options include:

  • 24-hour urinary free cortisol (UFC)
  • Late-night salivary cortisol
  • 2-day low-dose dexamethasone suppression test
  • Midnight serum cortisol 2, 1

Critical Pitfalls and Caveats

False Positives (Cortisol Fails to Suppress When Cushing is NOT Present)

Common causes include:

  • Inadequate dexamethasone levels: Due to malabsorption, rapid gut transit, chronic diarrhea, celiac disease, or drug interactions with CYP3A4 inducers (phenobarbital, carbamazepine, phenytoin, rifampin, St. John's wort) 2, 4
  • Elevated corticosteroid-binding globulin (CBG): From oral estrogens, pregnancy, or chronic active hepatitis, which increases total cortisol without increasing free cortisol 2, 4
  • Pseudo-Cushing states: Depression, anxiety, alcoholism, obesity, polycystic ovary syndrome 1, 4

Solution: Measure dexamethasone levels simultaneously with cortisol to confirm adequate dosing 4

False Negatives (Cortisol Suppresses When Cushing IS Present)

This is the more dangerous scenario clinically and occurs in:

  • Mild Cushing syndrome: Sensitivity drops dramatically to only 18-41% in patients with mild or periodic hypercortisolism 5
  • Cyclic Cushing syndrome: Testing during a eucortisolemic phase will yield false reassurance 2, 6
  • Enhanced dexamethasone effect: From medications that inhibit dexamethasone metabolism (fluoxetine, cimetidine, diltiazem) 4
  • Decreased CBG/albumin: Such as in nephrotic syndrome 4

This is why the Endocrine Society recommends AGAINST using dexamethasone suppression tests in suspected cyclic Cushing syndrome, favoring instead UFC or midnight salivary cortisol. 2

Special Populations Where DST Should NOT Be Used

Avoid dexamethasone testing in:

  • Pregnancy: Use UFC instead 2
  • Patients on antiepileptic drugs (phenytoin, carbamazepine, phenobarbital): These enhance dexamethasone clearance; use nonsuppressed cortisol measurements instead 2
  • Suspected cyclic Cushing syndrome: Use UFC or midnight salivary cortisol 2

Clinical Algorithm

  1. Perform overnight 1-mg DST in patients with clinical suspicion for Cushing syndrome (excluding special populations above)

  2. Interpret morning cortisol:

    • <1.8 μg/dL: Cushing syndrome excluded (unless high pretest probability or cyclic disease suspected—then follow clinically or repeat testing) 2
    • ≥1.8 μg/dL: Proceed to step 3
  3. Confirm with second test (UFC, late-night salivary cortisol, or 2-day low-dose DST) 2

  4. If both tests concordantly abnormal: Proceed to determine etiology (ACTH level, imaging) 2

  5. If discordant results: Refer to endocrinology for further evaluation, consider dexamethasone level measurement, evaluate for pseudo-Cushing states, or follow longitudinally 2

The key insight is that the DST is an excellent screening test with high sensitivity in typical cases, but its performance degrades significantly in mild or cyclic disease—precisely the patients where diagnosis is most challenging. 5 This is why guidelines mandate two abnormal tests before pursuing invasive localization studies.

References

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Guideline

the diagnosis of cushing's syndrome: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2008

Research

An update on the overnight dexamethasone suppression test for the diagnosis of Cushing's syndrome: limitations in patients with mild and/or episodic hypercortisolism.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.